arrow
A

Ajay K. Gopal

university of washington
H指数:65
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia

绝对淋巴细胞计数单一进展在慢性淋巴细胞白血病中的发生率和临床影响

2026-09-010
PRE
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma

多中心ACCRU-LY-1804/CARiBOU临床试验(将阿糖胞苷、阿卡替尼和利妥昔单抗整合到 bortezomib为基础的门诊治疗方案中)在一线套细胞淋巴瘤中的结果

2026-06-170
PRE
CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia

靶向CD20的自体CAR T细胞疗法治疗华氏巨球蛋白血症

Blood
IF23.1
2026-01-010
OAAI
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for relapsed/refractory Large B-Cell Lymphoma

自体造血干细胞移植治疗复发/难治性大B细胞淋巴瘤中全身照射与单纯化疗预处理方案的比较

2025-10-140
PRE
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia

免疫表型对T细胞原淋巴细胞白血病临床疾病特征和预后的影响

2025-09-010
PRE
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

CD19靶向CAR T疗法治疗转化型滤泡性淋巴瘤:一项CIBMTR分析

2025-08-050
PRE
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma

剂量密集型 Brentuximab vedotin、异环磷酰胺、卡铂和依托泊苷在复发性/难治性经典霍奇金淋巴瘤二线治疗中的长期随访研究

2025-08-040
PRE
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

普利尔替克酸对细胞毒性皮肤T细胞淋巴瘤有效。

2025-06-190
OA
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

纳武利尤单抗联合罗特利珠单抗治疗复发或进展性B细胞恶性肿瘤的RELATIVITY-022研究

2025-03-050
OA
Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab plus AVD in Untreated Classic Hodgkin Lymphoma

尽管在接受Pembrolizumab联合AVD治疗的未经治疗经典型霍奇金淋巴瘤患者中频繁出现4级中性粒细胞减少,但发热性中性粒细胞减少的发生率较低。

BLOOD
IF23.1
2024-11-050
PRE
Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL- the Avenue-2 Trial

Acalabrutinib和Venetoclax(AV)联合治疗经治CLL/SLL患者2年——Avenue-2试验

BLOOD
IF23.1
2024-11-050
PRE